Business
Results for 12 months ended 30 June 2017
Results for 12 months ended 30 June 2017.
About this update from Animalcare Group Plc
[{"type":"text","content":"\n \nRNS Number : 7717R Animalcare Group PLC 25 September 2017 \n\nAnimalcare Group plc\n(\"Animalcare\" or the \"Group\")\n \n Results for the twelve month period ended 30th June 2017\nProforma Interim Results for the enlarged group post the Acquisition of Ecuphar\n \nAnimalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, announces its interim results for the twelve month period ended 30th June 2017. These interim results constitute the second interim period in an eighteen month accounting period to 31st December 2017. This follows the Group's change of accounting reference date to 31st December further to the successful acquisition (\"the Acquisition\") of Ecuphar NV (\"Ecuphar\") completed on 13th July 2017.\n \nFollowing a very strong first half of the financial year for Animalcare, the Board is pleased to announce that pre-merger trading for the twelve months ended 30th June 2017 was in line with the Board's and market expectations. Total revenues for the twelve months were up 7.9% at £15.87m (FY16: £14.70m) and underlying operating profits increased by 11.8% to £3.57m (FY16: £3.19m).\n \nFinancial Summary for the twelve months ended 30th June 2017 (prior to the Acquisition)\n \n\n\n\n\n\n\n\nTwelve months ended 30th June 2017\n\n\nYear ended 30th June 2016\n\n\n% change\n\n\n\n\nRevenue\n\n\n£15.87m\n\n\n£14.70m\n\n\n+7.9%\n\n\n\n\n\n\nUnderlying* operating profit\n\n\n£3.57m\n\n\n£3.19m\n\n\n+11.8%\n\n\n\n\nUnderlying* EBITDA\n\n\n£3.96m\n\n\n£3.51m\n\n\n+13.0%\n\n\n\n\nBasic underlying* EPS\n\n\n14.9p\n\n\n13.0p\n\n\n+14.6%\n\n\n\n\nReported operating profit\n\n\n£2.81m\n\n\n£3.02m\n\n\n(7.0%)\n\n\n\n\nBasic EPS\n\n\n11.7p\n\n\n12.5p\n\n\n(6.4%)\n\n\n\n\nCash and cash equivalents\n\n\n£6.26m\n\n\n£7.11m\n\n\n(12.0%)\n\n\n\n\nInterim/Final dividend\n\n\n4.7p\n\n\n4.7p\n\n\n-\n\n\n\n\n \n* Underlying measures are before the effect of exceptional and other items. These are analysed in note 3. EBITDA is defined as the Group's profit before interest, taxation, depreciation and amortisation. \n \nHighlights\n· Strong revenue growth from Licensed Veterinary Medicines, up 17.2% to £10.83m (FY16: £9.24m) \n- driven by key pharmaceutical ranges (intravenous fluids, anaesthetics and analgesics) and revenue from ...